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Abbreviations 
- AEs (adverse events) 
- BMI (body mass index)  
- BP (blood pressure) 
- FDA (Food and Drug Administration) 
- HVLT-R (Hopkin's Verbal Learning Test)  
- ITT (Intention to Treat population) 
- mITT (modified Intention to Treat population) 
- MOAA/S (Modified Observer's Assessment of Alertness/Sedation),  
- SpO2 (mean oxygen saturation level) 
- PP (Per Protocol population) 
 
 
 
Abstract 
Background: Remimazolam is an ultrashort-acting benzodiazepine. 
Methods: We performed a randomized double-blind comparison of remimazolam to 
placebo for outpatient colonoscopy. This study design was a requirement of the U.S. 
Food and Drug Administration. An additional group was randomized to open-label 
midazolam administered according to its package insert instructions (randomization ratio 
for remimazolam:placebo:midazolam was 30:6:10). Study medications were administered 
under the supervision of the endoscopist, without any involvement of an anesthesia 
specialist. Patients were given 50 to 75 µg of fentanyl before receiving study medications. 
Patients who failed to achieve adequate sedation in any arm were rescued with 
midazolam dosed at the investigator’s discretion. The primary endpoint was a composite 
that required 3 criteria be met: completion of the colonoscopy, no need for rescue 
medication, and ≤5 doses of remimazolam or placebo in any 15-minute interval (≤3 doses 
of midazolam in any 12-minute interval in the open-label midazolam arm). 
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Results: There were 461 randomized patients in 12 U.S. sites. The primary endpoint was 
met for remimazolam, placebo, and midazolam in 91.3%, 1.7%, and 25.2% of patients, 
respectively (P< 0.0001 for remimazolam vs placebo). Patients administered 
remimazolam received less fentanyl, had faster recovery of neuropsychiatric function, 
were ready for discharge faster, and felt back to normal faster than patients with both 
placebo and midazolam. Hypotension was less frequent with remimazolam and hypoxia 
occurred in 1% of subjects with remimazolam or midazolam. There were no treatment-
emergent serious adverse events. 
Conclusion: Remimazolam can be safely administered under the supervision of 
endoscopists for outpatient colonoscopy and allows faster recovery of neuropsychiatric 
function compared with placebo (midazolam rescue) and midazolam. 
 
Introduction 
Endoscopic sedation is generally based on either midazolam or propofol, with the 
percentage of cases in the United States using propofol significantly increasing over the 
past two decades 1,2.  
Midazolam is usually given with an opioid 1. Advantages of midazolam include excellent 
amnesia, easy titration, and widespread acceptance of administration by endoscopists. 
Disadvantages of midazolam include greater cumulative effects due to a long-acting 
metabolite that causes slow recovery of neuropsychiatric function relative to propofol 3,4.  
Propofol can be administered in combination with an opioid and/or benzodiazepine, and 
titrated to moderate sedation 5. Propofol has a rapid onset and offset of action and there is 
a widespread perception that its advantages are maximized when administered as a single 
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agent, which usually results in deep sedation and has led to restrictions that frequently 
confine its administration to anesthesia specialists. The increasing use of propofol for 
endoscopic sedation is associated with improved patient satisfaction 6, but is not cost-
effective with regard to safety endpoints 7, and has been associated with high rates of 
aspiration pneumonia 8,9.  
Remimazolam is an ultrashort-acting benzodiazepine in development for procedural 
sedation 10. Like midazolam, remimazolam acts on GABA receptors to induce sedation. 
Unlike midazolam, remimazolam is metabolized by tissue esterases. Remimazolam 
differs from all other benzodiazepines by its carboxylic ester linkage, enabling its rapid 
breakdown to inactive metabolites only. The mean terminal elimination half-life of 
remimazolam is 0.75 hours, and that of midazolam is 4.3 hours 11,12. In phase II trials, 
remimazolam provided adequate procedural sedation for endoscopy, and faster recovery, 
than midazolam 13,14.  
We describe a prospective, randomized, parallel group study comparing remimazolam to 
placebo (blindly). The comparison to placebo was required by the U.S. Food and Drug 
Administration (FDA), which sought data on the performance of fentanyl plus 
remimazolam compared with fentanyl alone. To provide information on the relative 
performance of remimazolam and midazolam, we included an open-label arm of 
midazolam. However, the FDA required that midazolam be administered according to its 
package insert. Thus, neither the placebo arm nor the midazolam arm reflect usual 
clinical practice. The study was initiated at 13 sites in the United States (with 
12 contributing patients), in patients with American Society of Anesthesiology risk class 
I to III. All patients received an initial dose of 75 µg of fentanyl (plus repeated 25 µg 
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top-up doses to a total of up to 200 µg) during the first 80% of the study, which we 
lowered to 50 µg for the last 20% of the study. All sedation was given under the 
supervision of the endoscopist.  
Methods 
Overall design 
This study was a prospective, randomized, placebo and active controlled, multicenter, 
parallel group study comparing remimazolam to placebo in a double-blind manner, with 
an open-label midazolam arm. The composite primary endpoint and secondary endpoints 
for the sedation level are summarized in Table 1. The blinded comparison of 
remimazolam to placebo was requested by the US FDA. Patients were undergoing 
diagnostic or therapeutic colonoscopy. Four hundred and sixty-one patients were 
randomized into one of three groups: remimazolam, placebo, or open label midazolam in 
a ratio of 30:6:10.  
Figure 1 shows the flow of the study design.  Supplementary Table 1 shows the 
procedures performed at each visit. All participating sites obtained Institutional Review 
Board approval for participation. Patients were recruited between April 2015 and April 
2016.  The trial was registered at ClinicalTrials.gov with registration number 
NCT02290873. 
On the day of colonoscopy, all patients received up to 1,000 mL of 0.9% NaCl solution 
as an intravenous (IV) drip starting before the procedure. All patients received fentanyl 
before the assigned study sedative medication. For the first 80% of the study, patients 
received an initial dose of 75 µg of fentanyl (or a suitably reduced dose for elderly and 
debilitated patients). For the last 20% of the study, the initial fentanyl dose was reduced 
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to a maximum of 50 µg. This change was made at the request of the Data Safety 
Monitoring Board because the number of patients in the placebo/remimazolam group in 
the pre-amended portion of the study had transiently reached Modified Observer’s 
Assessment of Alertness/Sedation Scale (MOAA/S: see Table 2) scores of 0 could be 
regarded a safety issue, although no safety signal was associated with low MOAA/S 
scores. 
Supplemental oxygen at a rate of 4 L/min was administered to all patients before any 
medication and until the patient was fully alert (defined as 3 consecutive MOAA/S scores 
of 5). Patients were randomized to receive an initial single intravenous dose of 
remimazolam 5.0 mg or an equal volume of placebo over one minute in a blinded manner 
and colonoscopy was initiated when adequate sedation (MOAA/S ≤3) was achieved. 
Sedation was maintained by injection of further top-up doses of remimazolam 2.5 mg 
(1 mL) or an equal volume of placebo not earlier than two minutes apart after assessment 
of the sedative effect. For the maintenance phase of sedation, adequate sedation was pre-
defined as a MOAA/S of ≤4 in all study arms. The overall number of 
remimazolam/placebo doses was limited to 5 doses in any 15 minute window. If 5 doses 
(including the initial bolus) within any 15-minute window were not sufficient to obtain or 
maintain adequate sedation, the patient was designated a treatment failure. 
The overall number of midazolam doses was limited to three doses in any 12-minute 
window (as per the midazolam package insert: 1 dose equals 1 mg for a subject <60 years 
and 0.5 mg for those ≥60 years, debilitated or chronically ill). More than 3 doses required 
to obtain or maintain adequate sedation for colonoscopy within any 12-minute window 
was designated a treatment failure. 
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After determination of treatment failure in any study group, midazolam was the only 
sedative medication (rescue medication) permitted to complete the colonoscopy. Once a 
patient was designated a treatment failure, the dosing of rescue midazolam was at the 
endoscopist’s discretion. After the initial dose of fentanyl, pain alone during colonoscopy 
could be treated by top-up doses of fentanyl 25 µg every 5 to 10 minutes with a 
maximum dose of 200 µg. Fentanyl could not be administered if the respiratory rate was 
< 8 breaths/minute or the oxygen saturation level SpO2 was < 90%. 
Eligibility of study subjects 
The inclusion and exclusion criteria are listed in Table 3. 
Pre-procedure assessments 
Before initial administration of trial medication, patients underwent bowel preparation for 
colonoscopy, in accordance with the local standard bowel preparation protocol, baseline 
physical examinations were performed, hemodynamics and respiratory parameters,  
baseline MOAA/S score and HVLT-R were assessed, and baseline drowsiness was 
recorded. Preprocedure assessments are detailed in SupplementaryTable 1. 
Randomization and unblinding 
The randomization schedule was computer-generated using a permuted block algorithm. 
Randomization was assigned sequentially as patients entered the study without site 
stratification. Treatment unblinding was permitted only in a medical emergency. For 
patients assigned to remimazolam and placebo, all study personnel other than the 
pharmacist were blinded to the study agent throughout. Only the midazolam arm was 
open label. 
Intraprocedure assessments 
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After start of study drug administration, MOAA/S scores were recorded at 1, 1.5, 2, 2.5, 
and 3 minutes and further in 1-minute intervals until fully alert. After fully alert, 
MOAA/S scores were recorded every 5 minutes until Ready for Discharge, then every 10 
minutes (up to 90 minutes) until actual discharge (Supplementary Table 1).. Nadirs of 
heart rate, respiratory rate, and SpO2 were determined by continuous recording using 
Nellcor (Medtronic, Minneapolis, Minn) monitors. Implausible values were excluded 
from the analysis, based on the measurement range of the Nellcor machine (ranges were 
defined as follows: SpO2: 60% - 100%; pulse: 20 - 200 beats/minute; respiratory rate: 4-
40 breaths/min), as well as based on pre-defined “usable Nellcor data.” A Nellcor vital 
sign measurement was considered “usable” if measurements were within the defined 
ranges, there was no delay >2 minutes between start of study medication and start of 
Nellcor assessment, and at least 90% of readable Nellcor data (per parameter) within the 
observation time were available. Capnography was not used. 
Post-procedure assessments 
“Fully alert” was defined as the first of 3 consecutive MOAA/S measurements of 5 after 
the completion of the procedure. No attempt was made to wake the patient prematurely 
upon completion of the procedure. Blood was drawn for hematological and chemistry 
tests immediately before discharge and at follow-up. 
Safety assessments 
Safety was assessed by physical examination, vital signs (supine heart rate, systolic, 
diastolic, and mean BP, respiration rate and temperature), ECG, full blood count, 
standard chemistry panel, assessment of pulse oximetry measurements, pain on injection 
intensity rating, airway interventions (chin lift, jaw thrust, requirement of repositioning, 
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and/or manual or mechanical ventilation), and administration of additional fluids or 
medication or any interventions necessary due to a clinically relevant change in ECG.  
The following were considered adverse events (AEs). 
• Bradycardia: <40 beats/minute or a drop in heart rate of 20% or more from 
baseline that lasted continuously for ≥30 seconds. 
• Hypertension: systolic BP ≥180 mm Hg or diastolic BP to ≥100 mm Hg, or an 
increase of systolic or diastolic BP of 20% or more over baseline or necessitating 
medical intervention. 
• Hypotension: systolic BP ≤80 mm Hg or diastolic BP ≤40 mm Hg, or a fall in 
systolic or diastolic BP of 20% or more below baseline or necessitating medical 
intervention. 
• Respiratory rate decrease: < 8 breaths/minute. 
• Hypoxia: Oxygen saturation <90% for ≥1 minute, or any drop necessitating 
medical intervention. 
• Prolonged sedation: MOAA/S ≤4 for longer than 60 minutes after the last dose of 
study drug, including the need to administer flumazenil (at the investigator’s 
discretion). 
The following ECG parameters were collected: PR interval, RR interval, QRS interval, 
QT interval, and QTc interval (QT corrected, using Bazett and Fridericia formulae).  
All available study data were reviewed by a Data Monitoring Committee at 2, 4, 6, and 
then every 3 months after initiation of recruitment. 
The planned summary analysis of the incidence of MOAA/S scores (0-5) at select 
timepoints and an exploratory post-hoc analysis were performed. The aim of the 
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exploratory analysis was to assess the co-variance of MOAA/S scores with vital signs 
such as respiratory rate, heart rate, or SpO2. Every MOAA/S score reported was matched 
either with a corresponding vital sign value documented by the endoscopist or the nadir 
value of the Nellcor reported vitals (see Supplementary Table 2 for defined study 
populations). 
Sample size and power 
Sample size calculations for this superiority trial were based on the following 
assumptions: For a one-sided type I error rate of 0.025 and a target power of 90%, the 
assumption of a success rate of 30% for the placebo group and 90% for the remimazolam 
group led to sample sizes of 15 patients per treatment group. However, in order to reach 
an appropriate size for the safety database, 300 patients were required for the 
remimazolam group. The placebo group was set at 60 patients in order to avoid overly 
unequal group sizes. The power attained at different success rates for the placebo and 
remimazolam groups (type I error rate fixed as 0.025) is shown in Supplementary Table 
3. The midazolam group, which was not part of the primary confirmatory analysis, but is 
included for assay sensitivity, was set at 100 patients.  
Statistical methods 
All safety analyses presented in our current article were conducted on patients in the 
safety population whereas all efficacy analyses were performed on patients in the ITT 
population (Supplementary Table 2). The primary efficacy analysis was summarized 
descriptively for overall success and within each category for treatment group. Efficacy 
significance testing of time to event analyses were performed in a descriptive manner 
using the log rank test. For secondary efficacy variables descriptive summaries (n, mean, 
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SD, median, minimum, and maximum) were provided. Overall and pairwise comparisons 
at each time point were made using ANOVA models with treatment as the main effect. 
 
Results  
Randomization 
A total of 461 patients were randomized at 12 sites, including 298 to remimazolam, 60 to 
placebo, and 103 to open label midazolam. The mean age for the entire population was 
54.4 (+/- 10.12) years and 50.3% were female. Table 4 shows the mean age, sex, 
ethnicity, race, and body mass index (BMI) for patients (safety set) in the 3 study groups. 
There were no significant differences between the study groups for any demographic 
factor. No unblinding occurred. 
Primary efficacy variable  
Procedure success rates for the study groups and the rates at which each of the 
three components of procedure success (Table 1) were satisfied are shown in Table 5. 
Remimazolam was superior to placebo for overall procedural success, for lower or no 
need for a rescue medication, and for lower number of top-up doses required. The 
difference in success rates was 0.896 (95% CI, 0.851 - 0.942), with a significant 
difference between the two treatment groups (P<0.0001; Table 5). 
Fentanyl dosing  
The percentage of patients in each study group who received a 75 µg dose was similar 
between the study arms (Table 6). The total mean dose of fentanyl and the mean number 
of fentanyl top-ups were each lower with remimazolam (88.6 µg, 0.76) compared with 
placebo (121.3 µg, 1.93) and midazolam (106.9 µg, 1.34). The change in the mean 
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number of top-up doses of fentanyl administered after the initial dose of fentanyl was 
reduced from 75 µg to 50 µg was not remarkable.  
Pain at injection site  
When a VAS was used, the mean pain score for remimazolam for pain at the injection 
site (4.9) was not significantly different from  placebo (5.7; p=0.5902). The midazolam 
VAS pain score was 5.8. 
Sedative dosing  
The mean dose of remimazolam administered was 10.53 (± 3.98) mg, median 10.0 mg. 
Patients in the remimazolam arm received a mean of 2.22 (± 1.59) top-up doses of 
sedative, with a mean of 5.07 (± 0.55) for patients in the placebo arm and 2.97 (± 1.08) in 
the midazolam arm. Patients who did not require rescue sedative medication in the open-
label midazolam received a mean of 4.30 (± 1.62) mg of midazolam. 
Procedure times 
The time from the start of medication administration to reaching a MOAA/S of 3 largely 
reflects the study protocol, and was shorter for remimazolam at 5.1 (± 3.82) minutes 
compared with placebo 20.3 (± 4.34) minutes and less than midazolam 16.9 (± 6.31) 
minutes.  
Time to peak sedation, defined as time to the lowest MOAA/S score for the patient before 
the first top-up dose, was median 3.0 minutes (95% CI: 2.0, 3.0) in the remimazolam 
group. In the placebo group and the midazolam group, the median time to peak sedation 
could not be estimated as the majority of patients needed rescue sedative medication. The 
median time to start of procedure was shorter at 4.0 minutes in the remimazolam group 
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compared with placebo (19.5 minutes; 95% CI, 18.0; 21.0; p < 0.0001) and the 
midazolam group (19.0 minutes; 95% CI, 17.0; 20.0).  
Sedation level  
The MOAA/S scores according to procedure time are shown in Supplementary Figure 1. 
The mean deepest MOAA/S score for the entire 461 patients was 2.12 (± 1.14). The mean 
deepest MOAA/S score by treatment group was 1.95 (± 1.18) for remimazolam, which 
was lower than placebo 2.25 (± 0.97) and midazolam 2.54 (± 0.93). During the first 80% 
of the study, more patients in remimazolam group, as compared with those in the placebo 
and midazolam groups, reached MOAA/S scores of 0. Although these MOAS/S scores 
were not associated with any serious AEs, the Data Safety Monitoring Board 
recommended that the starting fentanyl dose be reduced to 50 µg for the remaining 20% 
of the study. After this dose reduction, the mean deepest MOAA/S score was not 
different from the mean deepest MOAA/S with remimazolam before the change. 
However, (1) the number of patients who reached MOAA/S scores of 0 was reduced to a 
level comparable with midazolam at the labeled dose and (2) the standard deviation was 
significantly smaller after fentanyl dose reduction (Supplementary Figure 1).  
The exploratory post-hoc analysis focused on co-variance of vital signs and the depth of 
sedation (MOAA/S score) (Supplementary Figure 2). Overall no positive correlation was 
found between the depth of sedation and the reported vital signs (respiratory rate, heart 
rate, and SpO2). The Nellcor reported vital signs were analyzed separately by pooling 
them into groups based on the sedation level of the subject at the specific time-point of 
vital sign assessment. This resulted in 3 comparable vital sign datasets: vitals assessed 
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during the time interval when subject experienced MOAA/S 0-1, MOAA/S 2-4, and 
MOAA/S 5, respectively.  
Recovery times 
Table 7shows recovery times for the 3 study groups. Recovery times were consistently 
shorter for remimazolam compared with placebo (P<0.001). The reported mean time 
from the end of the procedure to patients feeling completely “back to normal” was 
3.2 hours in the remimazolam group, compared with 5.8 hours with placebo (hazard ratio 
of 1.750; 95% CI, 1.311 - 2.336; P=0.0001). Mean recovery time was 6.1 hours in the 
midazolam group.  
Recovery of neuropsychiatric function 
There were no differences between study groups in the HLVT-R total raw scores, delayed 
recall, retention raw scores, or recognition discrimination at baseline. Table 8 shows the 
comparison of Hopkins scores between the different treatment arms at 5 minutes after the 
patient was judged fully alert. All the scores demonstrated better restoration of 
neuropsychiatric function after remimazolam compared with placebo and midazolam.  
Recall 
When the Brice questionnaire was used within 10 minutes of the patient reaching fully 
alert status, the percent of patients who said yes to the question “Can you remember 
anything?” was 29.2% for remimazolam, 28.3% for placebo, and 31.1% for midazolam. 
On the fourth visit, the scores for recall of the procedure (0=none of the procedure 
remembered and 10=all of it), showed a mean remimazolam score of 1.9, placebo 1.7, 
and midazolam 1.6. For the fourth visit follow-up Brice questionnaire VAS for 
satisfaction (0=completely dissatisfied; 10=completely satisfied), the mean remimazolam 
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score was 9.6, placebo 9.4, and midazolam 9.5. For the question, “Did you experience 
any untoward effects the day after the procedure,” the percent of patients who answered 
“yes” was 6.0% for remimazolam, 11.7% for placebo, and 7.8% for midazolam. 
Safety 
Table 9 lists the incidence of AEs and treatment emergent AEs for the 3 study groups. 
The incidence of hypotension was 61.8% with midazolam, 41.7% for placebo and 38.9% 
for remimazolam. The incidence of hypotension was the principal contributor to the main 
differences observed in treatment emergent AEs between remimazolam and midazolam. 
At the screening examination and the baseline examination, there were no differences 
among groups in body temperature, heart rate, systolic or diastolic BP, or oxygen 
saturation. The rates of treatment emergent AEs with remimazolam, placebo, and 
midazolam were 73.6%, 78.3%, and 91.2%, respectively (P<0.0001 remimazolam vs 
midazolam). Table 10 shows the nadirs for heart rate, respiratory rate, and oxygen 
saturation for the three groups. All of the mean nadirs were numerically lower with 
placebo and midazolam compared with remimazolam, except for oxygen saturation, 
which was not different between the arms. 
Laboratory safety parameters showed no clinically meaningful differences between 
treatment groups in the incidence of out-of-range values, all of which appeared related to 
bowel preparation.  
Discussion 
We report the results of a randomized, placebo-controlled, multicenter study comparing 
remimazolam to placebo in a blinded fashion and to an open label arm of midazolam, in 
outpatients undergoing colonoscopy. The study design was driven by consultation with 
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the FDA, and evaluated the sedative effect of remimazolam plus fentanyl to fentanyl 
alone. Because fentanyl is seldom administered in clinical practice as a single agent for 
colonoscopy, we elected to add a randomized, but open label, arm of midazolam in order 
to have an assessment of how remimazolam plus fentanyl compared with midazolam plus 
fentanyl, as the latter is a very commonly used sedative/analgesic combination in current 
colonoscopic practice. After consultation with FDA, we administered midazolam in the 
midazolam open label arm according to the instructions in the United States midazolam 
package insert, which is understood to be a slower and more cautious administration 
regimen for midazolam than is commonly used in clinical practice. Thus, the times to 
achieve various sedation endpoints in this study are likely prolonged in the placebo and 
midazolam arms because of the study protocol and may overstate the advantages of 
remimazolam with regard to the onset of the sedation. Conversely, the results likely 
understate the advantages of remimazolam for recovery because midazolam is generally 
administered more rapidly and in higher doses in clinical practice. Despite these 
limitations in study design, the study provides useful information about remimazolam as 
a sedative for colonoscopy.  The key finding is that fentanyl 50 to 75 µg, followed by 
remimazolam at an initial dose of 5 mg and subsequent doses of 2.5 mg as needed, 
resulted in adequate sedation for outpatient colonoscopy. The mean total dose of 
remimazolam used was 10.5 mg, indicating that the initial dose and 2 top-ups of 
remimazolam are sufficient for sedation in average patients. Importantly, remimazolam 
showed the most rapid values for recovery of neuropsychiatric function, readiness for 
discharge, and return to a feeling of complete normality consistent with previous data 14. 
Remimazolam did not produce pain at the injection site but produced amnesia for the 
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procedure comparable to midazolam. Finally, remimazolam resulted in no serious AEs. 
The absolute rates of AEs were higher in all arms of the study compared with previous 
trials 14, but this likely reflects differences in definitions of AEs between studies.  In the 
absence of serious AEs, the most important observation regarding AEs are the 
comparison of AE rates between study arms.  The rate of hypotension was lowest with 
remimazolam and the rate of hypoxia with remimazolam was comparable to the rate of 
hypoxia with midazolam.  
During the study, we lowered the usual dose of fentanyl given before any sedative from 
75 µg to 50 µg (at the recommendation of the Data Safety Monitoring Board). This was 
done because the number of patients that reached MOAA/S of 0 was considered a 
potential concern, although neither serious AEs were nor relevant changes in cardio-
respiratory parameters had been observed. This is consistent with the findings of Kim et 
al 15, which indicate that no response to a trapezius squeeze indicates the transition to 
anesthesia rather than representing surgical anesthesia. Reducing the dose of fentanyl 
reduced the occurrence of MOAA/S of 0 in this study to that of the low dose of 
midazolam recommended in its package insert. 
Reducing the dose of fentanyl from 75 µg to 50 µg did not adversely affect the 
advantageous features of remimazolam. This reduced dose of fentanyl and reduction of 
MOAA/S scores of 0 should improve the acceptability of remimazolam administration by 
non-anesthesia specialists.  With regard to sedation by remimazolam, we note that like 
other benzodiazepines, the sedative effects are reversible with flumazenil.     
During an exploratory analysis it was also demonstrated that vital signs do not correlate 
with MOAA/S scores, which is in agreement with the assessment of all Phase III studies 
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at the time of the decision to reduce the fentanyl dose. The same analysis stratified by 
treatment arms showed low variance of vital sign values in the remimazolam group, 
ranging between those reported for the midazolam and placebo group. 
In summary, remimazolam is a safe and effective sedative for outpatient colonoscopy 
when administration is supervised by endoscopists and allows more rapid recovery 
compared with placebo and midazolam. Remimazolam offers benefits to patients and 
endoscopists compared with midazolam, and the potential for lower costs to patients and 
insurers compared with propofol administered by healthcare providers trained in 
providing general anesthesia. 
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Tables 
 
Table 1: Primary and Secondary Outcome Variables 
Primary outcome measure 
• Success of procedure as measured by 
- Completion of colonoscopy and 
- No requirement for an alternative sedative and 
- In the case of remimazolam and placebo, no requirement for more than 5 top-ups 
of study medication within any 15-minute period. In the case of midazolam, no 
requirement for more than 3 doses in any 12-minute window. 
 
Secondary objectives 
• Time to start of procedure after administration of the first dose of medication 
• Time to peak sedation after administration of the first dose of medication 
• Times to readiness for discharge after the end of procedure 
• Times to fully alert (first of 3 MOAA/S scores of 5 after end of procedure) 
• Recall of the procedure by the Brice questionnaire when fully alert and on Day 4 
• Changes to the patient’s cognitive function by the HVLT-R administered before 
study medication and after fully alert 
• Safety of multiple doses of remimazolam after a standard dose of fentanyl 
• Ready to discharge 30, 60, and 90 minutes post injection of the initial dose 
• Drowsiness visual analogue scale to assess for signs of re-sedation 
• Requirement for flumazenil during the procedure 
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• Patient’s self-evaluation of “back-to-normal” after the procedure 
• Pain on injection at application of study medication 
• Population PK (pharmacokinetics) in patients below 65 years of age, and patients 
aged 65-74 
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Table 2: Description of Modified Observer’s Alertness/Sedation (MOAA/S) Scale 
Scores 
Score Description 
5 Responds readily to name spoken in normal tone 
4 Lethargic response to name spoken in normal tone 
3 Responds only after name is called loudly and/or repeatedly 
2 Responds only after mild prodding or shaking 
1 Responds only after painful trapezius squeeze 
0 No response after painful trapezius squeeze 
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Table 3: Study Inclusion and Exclusion Criteria 
 
Inclusion Criteria 
- Male and female patients, aged ≥18, scheduled to undergo a diagnostic or 
therapeutic colonoscopy (therapeutic procedures may include hemostasis, 
resection, ablation decompression, foreign body extraction, for example). 
- American Society of Anesthesiologists Score 1 through 3. 
- Body mass index ≤40 kg/m2. 
- For female patients with child-bearing potential, negative result of pregnancy test 
(serum or urine) as well as use of birth control during the study period (from the 
time of consent until all specified observations are completed). 
- Patient voluntarily signs and dates an Informed Consent Form that is approved by 
an Institutional Review Board before the conduct of any study procedure. 
- Patient is willing and able to comply with study requirements and return for a 
follow-up visit on day 4 (+3/-1 days) after the colonoscopy. 
 
Exclusion Criteria 
- Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, 
naloxone, or a medical condition such that these agents are contraindicated. 
- Chronic use of benzodiazepines for any indication (eg, insomnia, anxiety, 
spasticity). 
- Chronic use of opioids for any indication. 
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- Female patients with a positive serum human chorionic gonadotropin pregnancy 
test at screening or baseline. 
- Lactating female patients. 
- Patients with positive drugs of abuse screen or a positive serum ethanol at 
baseline. 
- Patient with a history of drug or ethanol abuse within the past 2 years. 
- Patients in receipt of any investigational drug within 30 days or less than 7 half-
lives (whichever is longer) before screening, or scheduled to receive one during 
the study period. 
- Participation in any previous clinical trial with remimazolam. 
- Patients with an inability to communicate well in English with the investigator, or 
deemed unsuitable according to the investigator (in each case providing a reason). 
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Table 4: Demographics of the 3 study arms 
 
 
 Remimazolam Placebo Midazolam TOTAL 
  N=296 
n (%) 
N=60 
n (%) 
N=102 
n (%) 
N=458 
n (%) 
Age 
[years] 
N 296   60 102 458  
Mean 54.4  56.0 55.6 54.9  
 
SD 10.12 9.51  10.15  10.05 
 
Minimum 19  24 20 19  
 
Median 55.0  56.0 57.0 55.5  
 
Maximum 80  92 74 92  
Age 
Group 
[years] 
<65 254 (85.8%) 53 (88.3%)  88 (86.3%)  395 (86.2%) 
≥65 42 (14.2%) 7 (11.7%)  14 (13.7%)  63 (13.8%) 
Gender Male 147 (49.7%) 25 (41.7%)  46 (45.1%)  218 (47.6%) 
 
Female 149 (50.3%) 35 (58.3%)  56 (54.9%)  240 (52.4%) 
Race American Indian or 
Alaska Native 
1 (0.3%) 0 (0.0%)  0 (0.0%)  1 (0.2%) 
 
Asian 18 (6.1%) 3 (5.0%)  10 (9.8%)  31 (6.8%) 
 
Black or African 
American 
52 (17.6%) 14 (23.3%)  14 (13.7%)  80 (17.5%) 
 
Native Hawaiian or 
Other Pacific 
Islander 
1 (0.3%) 0 (0.0%)  0 (0.0%)  1 (0.2%) 
 
White 220 (74.3%) 43 (71.7%)  76 (74.5%)  339 (74.0%) 
 
Other 3 (1.0%) 0 (0.0%)  1 (1.0%)  4 (0.9%) 
 
Multiple 1 (0.3%) 0 (0.0%) 1 (1.0%) 2 (0.4%) 
Ethnicity Hispanic or Latino 46 (15.5%) 10 (16.7%) 17 (16.7%) 73 (15.9%) 
 
Not Hispanic or 
Latino 
250 (84.5%) 50 (83.3%) 85 (83.3%) 385 (84.1%)  
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 Remimazolam Placebo Midazolam TOTAL 
  N=296 
n (%) 
N=60 
n (%) 
N=102 
n (%) 
N=458 
n (%) 
Height 
[cm] 
N 296  60   102   458  
Mean 170.1   167.8   169.5   169.6  
 
SD  10.36 10.24 11.15 10.53 
 
Minimum 144   147   143   143  
 
Median 170.0   166.0   170.0   170.0  
 
Maximum 193   193   200   200  
Weight 
[kg] 
N 296  60   102   458  
Mean  83.2  84.6  81.9  83.1  
 
SD  17.39  19.90  16.24 17.47  
 
Minimum  40   49   52  40 
 
Median  83.7   80.8   81.8  82.1 
 
Maximum 128  144  126   144 
BMI 
[kg/m2] 
N 296   60  102   458 
Mean  28.9   30.0   28.8  29.0 
 
SD 4.72 5.31 4.75  4.81  
 
Minimum 17 19 17  17  
 
Median  29.1  29.0 28.2  28.7  
 
Maximum  40  40 39  40  
ASA-PS 
score 
N 296 60 102 458 
 
I 95 11 37 143 
 
II 179 45 61 285 
 
III 22 4 4 30 
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Table 5: Primary Efficacy Variable: Overall Procedural Success (ITT set) 
 
 Remimazolam Placebo Midazolam 
Procedure Success  91.3% 1.70% 25.2% 
Colonoscopy Completed 97.7% 98.3% 98.1% 
-*/No need for rescue medication 96.6% 5.0% 35.9% 
No more than 5 “top-ups” in any 15 
minute interval  (for midazolam, 3 
“top-ups” in any 12 minute interval) 
94.0% 26.7% 45.6% 
 
Comparison 
Difference in 
Rates 
95% Confidence Interval P-Value 
  Lower Upper  
Remimazolam vs Placebo 0.8961 0.8505 0.9416 <0.0001 
Remimazolam vs Midazolam 0.6603  0.5705  0.7501   
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Table 6: Fentanyl Dosing in the Study Arms 
 
 Remimazolam Placebo Midazolam P value for 
Remimazolam 
Versus 
Placebo 
Received the 75 µg initial dose 79.7% 80.0% 77.5% 0.88 
Mean total fentanyl-µg 88.6 121.3 106.9 .0000 
Mean number of fentanyl top ups 0.76 1.93 1.34 .0000 
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Table 7: Mean Times for Recovery (Minutes)  
 
 Remimazolam Placebo Midazolam P value  
(remimazolam 
vs placebo) 
From end of procedure to fully alert 7.35 (5.78) 21.95 (17.74) 15.84 (11.57) <0.0001 
From procedure and until walking test 
passed 
43.81 (13.26) 54.50 (20.26) 48.75 (14.44) <0.0001 
From last study medication until 
walking test passed 
50.94 (13.84) 65.10 (18.77) 58.07 (14.4) <0.0001 
From start of medication to ready-for-
discharge 
60.34 (13.7 87.95 (21.07) 77.27 (15.85) <0.0001 
End of study medication to back to 
normal 
330.71 (484.09) 572.67 (626.75) 553.11 (502.92) 0.001 
Time to fully alert from last dose of 
IMP/rescue [min] 
14.36 (5.39) 31.93 (16.81) 25.19 (11.26) <0.0001 
Time to ready for discharge from end 
of procedure [min] 
42.65 (13.74) 53.18 (20.55) 47.92 (14.68) <0.0001 
Time to ready for discharge from last 
dose of IMP/rescue [min] 
49.78 (14.33 63.78 (19.09) 57.44 (14.56) <0.0001 
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Table 8: Hopkins Verbal Learning Test Scores 5 Minutes After Full Alertness 
 
Parameter/ 
Timepoint 
Comparison Mean 
Difference 
Between  
95% Confidence Interval P value 
  Treatments Lower Upper  
Total Recall 
5 minutes after   
 fully alert 
Remimazolam vs Placebo 4.69 2.52 6.86 <0.0001 
Remimazolam vs Midazolam 3.94 2.22 5.66  
 
Delayed 
Recall 
5 minutes after   
 fully alert 
Remimazolam vs Placebo 3.74 -0.47 7.96 0.0816 
Remimazolam vs Midazolam 2.97 -0.16 6.09  
 
Retention 
5 minutes after   
 fully alert 
Remimazolam vs Placebo 4.48 -2.82 11.79 0.2273 
Remimazolam vs Midazolam 4.58 -1.04 10.19  
 
RDI 
5 minutes after   
 fully alert 
Remimazolam vs Placebo 6.35 2.25 10.46 0.0025 
Remimazolam vs Midazolam 7.43 4.53 10.33  
RDI = Recognition Discrimination Index 
Note: Statistics (mean difference and confidence intervals based on Least Square Means and P value) are 
from analysis of variance with treatment and age group as main effects. 
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Table9: Incidence of treatment emergent adverse events  
 
System Organ Class Remimazolam Placebo Midazolam Total 
  Preferred Term N=296 
n (%) 
N=60 
n (%) 
N=102 
n (%) 
N=458 
 
    
Any treatment-emergent 
 adverse events  
218 (73.6%) 47 (78.3%) 93 (91.2%) 358 (78.2%) 
Vascular disorders 184 (62.2%) 41 (68.3%) 83 (81.4%) 308 (67.2%) 
 Hypotension 115 (38.9%) 25 (41.7%) 63 (61.8%) 203 (44.3%) 
 Hypertension 59 (19.9%) 17 (28.3%) 18 (17.6%) 94 (20.5%) 
 Diastolic hypertension 29 (9.8%) 6 (10.0%) 9 (8.8%) 44 (9.6%) 
 Diastolic hypotension 23 (7.8%) 4 (6.7%) 9 (8.8%) 36 (7.9%) 
 Systolic hypertension 16 (5.4%) 5 (8.3%) 6 (5.9%) 27 (5.9%) 
Cardiac disorders 53 (17.9%) 14 (23.3%) 26 (25.5%) 93 (20.3%) 
  Bradycardia 33 (11.1%) 7 (11.7%) 16 (15.7%) 56 (12.2%) 
 Tachycardia 23 (7.8%) 7 (11.7%) 13 (12.7%) 43 (9.4%) 
Respiratory, thoracic and 
mediastinal disorders 
11 (3.7%) 4 (6.7%)  6 (5.9%)  21 (4.6%)  
  Bradypnoea 4 (1.4%)  2 (3.3%)  3 (2.9%)  9 (2.0%)  
 Hypoxia 3 (1.0%)  2 (3.3%)  1 (1.0%)  6 (1.3%)  
 Respiratory depression 1 (0.3%)  0 (0.0%)  1 (1.0%)  2 (0.4%)  
Gastrointestinal disorders 8 (2.7%) 5 (8.3%) 3 (2.9%) 16 (3.5%) 
  Nausea 5 (1.7%) 4 (6.7%) 2 (2.0%) 11 (2.4%) 
 Vomiting 3 (1.0%) 2 (3.3%) 0 (0.0%) 5 (1.1%) 
 Diarrhoea 0 (0.0%) 1 (1.7%) 1 (1.0%) 2 (0.4%) 
Nervous system disorders 11 (3.7%) 0 (0.0%) 3 (2.9%) 14 (3.1%) 
  Headache 5 (1.7%) 0 (0.0%) 3 (2.9%) 8 (1.7%) 
 Dizziness 3 (1.0%) 0 (0.0%) 0 (0.0%) 3 (0.7%) 
 Presyncope 2 (0.7%) 0 (0.0%) 0 (0.0%) 2 (0.4%) 
Investigations 8 (2.7%) 1 (1.7%) 4 (3.9%) 13 (2.8%) 
  Respiratory rate decreased 3 (1.0%) 0 (0.0%) 2 (2.0%) 5 (1.1%) 
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System Organ Class Remimazolam Placebo Midazolam Total 
  Preferred Term N=296 
n (%) 
N=60 
n (%) 
N=102 
n (%) 
N=458 
 
    
 Blood pressure diastolic increased 3 (1.0%) 0 (0.0%) 1 (1.0%) 4 (0.9%) 
 Blood pressure diastolic decreased 2 (0.7%) 0 (0.0%) 0 (0.0%) 2 (0.4%) 
 Blood pressure systolic decreased 1 (0.3%) 0 (0.0%) 1 (1.0%) 2 (0.4%) 
 Blood pressure systolic increased 2 (0.7%) 0 (0.0%) 0 (0.0%) 2 (0.4%) 
 Haematocrit decreased 1 (0.3%) 1 (1.7%) 0 (0.0%) 2 (0.4%) 
 Haemoglobin decreased 1 (0.3%) 1 (1.7%) 0 (0.0%) 2 (0.4%) 
Infections and infestations 2 (0.7%) 1 (1.7%) 1 (1.0%) 4 (0.9%) 
General disorders and 
administration site conditions 
2 (0.7%) 0 (0.0%) 1 (1.0%) 3 (0.7%) 
Metabolism and nutrition 
disorders 
2 (0.7%) 0 (0.0%) 1 (1.0%) 3 (0.7%) 
Injury, poisoning and procedural 
complications 
0 (0.0%) 1 (1.7%) 1 (1.0%) 2 (0.4%) 
 Contusion 0 (0.0%) 1 (1.7%) 1 (1.0%) 2 (0.4%) 
Musculoskeletal and connective 
tissue disorders 
0 (0.0%) 1 (1.7%) 1 (1.0%) 2 (0.4%) 
 Back pain 0 (0.0%) 1 (1.7%) 1 (1.0%) 2 (0.4%) 
Eye disorders 0 (0.0%) 0 (0.0%) 1 (1.0%) 1 (0.2%) 
Psychiatric disorders 1 (0.3%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 
Skin and subcutaneous tissue 
disorders 
0 (0.0%) 0 (0.0%) 1 (1.0%) 1 (0.2%) 
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Table 10: Continuous Monitoring of Vital Signs - Nadirs (Applicable Safety [Nellcor] 
Populations) 
 
Parameter Sample  Remimazolam Placebo Midazolam Total 
 Characteristics     
Heart Rate 
(beats/minute) 
N 214 40 71 325 
Mean 61.5 59.3 57.5 60.4 
 
Std. Deviation 10.90 10.58 7.99 10.40 
 Minimum 34 38 40 34 
 Lower Quartile 55.0  52.0 53.0  54.0  
 Median 61.0 59.0 57.0 59.0 
 Upper Quartile 68.0  65.5 64.0 66.0 
 Maximum 100 86 81 100 
Respiratory 
Rate 
(breaths/minute) 
-  
Lowest Nellcor 
Value 
(calculated) 
N 116 19 37 172 
Mean 10.3 8.9 9.2 9.9  
Std. Deviation 2.43  2.61 1.99  2.42 
Minimum 5 6 5 5 
 Lower Quartile 9.0 7.0  8.0  8.0  
 Median 11.0 8.0  9.0 10.0  
 Upper Quartile 12.0 11.0 10.0 12.0  
 Maximum 19 15 14 19 
Oxygen 
Saturation (%) 
– Lowest Nellcor 
Value 
(calculated) 
N 216 42 71 329 
Mean 93.5  88.5 93.1  92.7  
Std. Deviation 5.71 9.07  6.53 6.59 
 Minimum 63 56 65 56 
 Lower Quartile 91.0 87.0 91.0  90.0  
 Median 95.0 91.0 95.0 95.0 
 Upper Quartile 97.0 94.0 97.0 97.0 
 Maximum 100 98 100 100 
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Figures 
Figure 1: Study Diagram 
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Supplementary Material 
Supplementary Table 1: Day 1 – Assessments based on dosing time 
Dosing Day (Day 1) 
Procedures  
Pre-dose 
Dosing of 
trial 
medication1 
Post-dose 
within 
3 hr 
within 
30 min. 
within 
15 min. 
1min. 
pre-dose  1 min. 
1.5 
min. 2 min. 
2.5 
min. 3 min. 5 min. 10 min. Every 5 minutes until fully alert  
Review inclusion & 
exclusion criteria X                  
Medical & medication 
histories X                                   
Adverse Events X                                   
Concomitant medication X                                   
Physical examination x (B)                                   
Weight x (B)                                   
Body temperature x (B)  x   
 
            
x 
(post pro-
cedure) 
    
x (at 
fully 
alert) 
      
x 
(at discharge) 
Clinical laboratory tests  x (B)                                 x (at discharge) 
3 lead ECG 
  
xx xx xx xx xx xx xx xx xx xx xx xx xx xx xx xx 
3 lead ECG 
documentation in CRF 5   x x    x   x x x x x x x x 
12-lead ECG  x (B)         x           x   x6  
 
x6    x6   
Urine pregnancy test X                                   
Urine drug-of abuse test X                                   
Ethanol saliva test X                                   
Randomization X                                   
HVLT-R Learning 
(within 
45 min)                 x                
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Dosing Day (Day 1) 
Procedures  
Pre-dose 
Dosing of 
trial 
medication1 
Post-dose 
within 
3 hr 
within 
30 min. 
within 
15 min. 
1min. 
pre-dose  1 min. 
1.5 
min. 2 min. 
2.5 
min. 3 min. 5 min. 10 min. Every 5 minutes until fully alert  
Hemodynamic 
parameters (HR, BP)7,8  X x x (B) x        x     x x x x  x x  x x 
Normal saline   xx xx xx  
xx up to 1000 
mL administered, 
if fluid status 
allows 
xx xx xx xx xx xx xx xx 
until end of  
colonoscopy procedure 
MOAA/S2     x (B)     x x x x every minute until fully alert, then every 5 min until ready for discharge, then every 10 min until 
actual discharge 
Respiratory rate8 
  
x (B) xx xx xx xx xx xx xx xx xx xx xx xx xx xx xx 
RR (document in CRF) 
  
x (B) x 
   
x 
  
x x x x x x x x 
SpO23 (pulse oximetry)     x (B) xx xx xx xx xx xx xx xx xx xx xx xx xx xx  xx  
SpO27,8 (documentation 
in CRF)     x (B) x        x     x x x x x x x  x 
Airway management 
assessment 
    x                               
Supplemental O2              
(nasal prongs)      xx xx xx xx xx xx xx xx xx xx xx xx  xx  xx xx xx 
Fentanyl       
 
 x Supplemental doses q 5-10 min until adequate analgesia or 200 µg maximum dose 
Pain on injection Learning     
 
 x 
or as soon as 
poss..    
 
     
      
 
Drowsiness VAS4 
 
  
x 
   
x 
 
 
x x 15 
 
25 35 45 60 
Brice 
 
       
 
  
x 
(within 
10 
mins) 
      
(B) = Baseline values, x = Single action, xx = Continuous action, mins = minutes CRF case report form, HR heart rate, BP blood pressure, RR respiratory rate, VAS visual 
analogue scale 
NOTE: 1 Trial medication: Loading dose of randomized study drug start defines t=0, supplemental doses as per protocol. 
2
 Colonoscopy starts at sufficient sedation (MOAA/S ≤3), duration as necessary (MOAA/S ≤4), at the discretion of the investigator. 
 
3
 90 minute value only if patient is still sedated. 
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4
 If possible by patient. 
 
5
 Documented by running a strip. 
 
6
 after first dose, 5 minutes after dosing and every 10 minutes until the end of the procedure if possible, and also 5 minutes after the end of the procedure. 
 
7 In addition to the times specified above, blood pressure, heart rate, and SpO2 will be recorded immediately before, and 2 minutes after each additional dose of 
fentanyl 
 
8
 Vital signs (heart rate, systolic and diastolic BP, respiratory rate, and SpO2) will be recorded when an AE with a respiratory or cardiovascular focus has been 
observed. 
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Supplementary Table 2:  Analysis Sets and Populations Across Groups 
 
 
Analysis Sets 
 
Remimazolam 
N=298 
n (%) 
Placebo 
N=60 
n (%) 
Midazolam 
N=103 
n (%) 
TOTAL 
N=461 
n (%) 
Randomized 298 (100.0%) 60 (100.0%) 103 (100.0%) 461 (100.0%) 
Safety Populationa 296 (99.3%) 60 (100.0%) 102 (99.0%) 458 (99.3%) 
Safety Population (Nellcor) - At least one 
Parameter usableb 
216 (72.5%) 42 (70.0%) 71 (68.9%) 329 (71.4%) 
Safety Population (Nellcor) - Usable Heart Rateb1 214 (71.8%) 40 (66.7%) 71 (68.9%) 325 (70.5%) 
Safety Population (Nellcor) - Usable Respiratory 
Rateb2 
116 (38.9%) 19 (31.7%) 37 (35.9%) 172 (37.3%) 
Safety Population (Nellcor) - Usable Oxygen 
Saturationb3 
216 (72.5%) 42 (70.0%) 71 (68.9%) 329 (71.4%) 
Intention-to-treat Analysis Setc 298 (100.0%) 60 (100.0%) 103 (100.0%) 461 (100.0%) 
Modified Intention-to-treat Analysis Setd 296 (99.3%) 60 (100.0%) 102 (99.0%) 458 (99.3%) 
Per-Protocol Analysis Sete 228 (76.5%) 44 (73.3%) 77 (74.8%) 349 (75.7%) 
     
N = number of patients; n = number of observations 
a The Safety Population consists of all randomized patients who received any amount of study drug and were analyzed as treated. 
b Safety Population (Nellcor) consists of all patients in the Safety Population who had usable Nellcor data in at least one parameter 
b1 Consists of all patients in the Safety Population who had usable Heart Rate data (Nellcor) 
b2 Consists of all patients in the Safety Population who had usable Respiratory Rate data (Nellcor) 
b3 Consists of all patients in the Safety Population who had usable Oxygen Saturation data (Nellcor) 
c The Intent-to-treat analysis set (ITT) includes all patients who were randomized and were analyzed as randomized. 
d The Modified Intent-to-treat analysis set (mITT) includes all patients in the ITT population who received at least one complete dose 
of study medication. 
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Supplementary Table 3: Power Attained at Different Success Rates for the Placebo and 
Remimazolam Groups* 
 
                     
                           
Placebo Remimazolam 
20% 25% 30% 
60% 100% 99.96% 99.33% 
70% 100% 100% 100% 
80% 100% 100% 100% 
90% 100% 100% 100% 
 *type I error rate fixed as 0.025):  
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Supplementary Table 4: Mean and SD of Vital Signs Reported by the Nellcor by 
Treatment arm at Different Sedation Levels 
 
Heart Rate (beats/minute) 
Sedation Level Treatment arm Count Mean Median SD 
MOAA/S 0-1 
MIDAZOLAM 27 58.52 61 7.97 
PLACEBO 26 64.15 64 4.62 
REMIMAZOLAM 328 67 66 10.66 
MOAA/S 2-4 
MIDAZOLAM 2590 63.51 63 9.12 
PLACEBO 1676 66.58 67 11.16 
REMIMAZOLAM 4708 68.74 68 11.6 
MOAA/S 5 
MIDAZOLAM 1258 66.07 65 10.6 
PLACEBO 1013 67.96 68 11.57 
REMIMAZOLAM 2143 65.75 64 11.94 
Respiratory Rate (breath/minute) 
Sedation Level Count Mean Median SD 
MOAA/S 0-1 
MIDAZOLAM 25 11.36 11 2.14 
PLACEBO 23 13.43 14 4.52 
REMIMAZOLAM 309 12.57 12 2.41 
MOAA/S 2-4 
MIDAZOLAM 2260 13.12 13 3.58 
PLACEBO 1347 13.98 14 3.57 
REMIMAZOLAM 4246 13.63 13 3.4 
MOAA/S 5 
MIDAZOLAM 1043 12.56 12 3.33 
PLACEBO 847 12.91 13 3.51 
REMIMAZOLAM 1922 13.03 13 3.64 
SpO2 (%) 
Sedation Level Count Mean Median SD 
MOAA/S 0-1 
MIDAZOLAM 27 99.11 99 0.89 
PLACEBO 26 95.96 97 2.14 
REMIMAZOLAM 328 97.99 99 3.09 
MOAA/S 2-4 MIDAZOLAM 2590 97.55 98 2.92 
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PLACEBO 1679 97.11 98 3.86 
REMIMAZOLAM 4713 97.73 99 2.99 
MOAA/S 5 
MIDAZOLAM 1259 97.14 98 4.03 
PLACEBO 1015 97.63 99 3.74 
REMIMAZOLAM 2146 96.27 97 4.23 
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Supplementary Figure 1: Comparison of MOAA/S - Remimazolam plus fentanyl 75 vs 
50 µg 
Supplementary Figure 2: Analysis of Variance of Vital Signs by MOAA/S and by 
Treatment Arm 
Red lines are marking the defined the thresholds defined for reporting AEs. Figure A, 
Heart Rate. B, Respiratory Rate. C, SpO2. 
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